Table 1. Patient demographics and tumour characteristics.
|
Age (years) |
n=20 |
| Median |
51.8 |
| Range |
31.6–67.0 |
| Inflammatory carcinoma |
2 (10%) |
| IDC |
19 (95%) |
| ILC |
1 (5%) |
| Grade 1 |
0 (0%) |
| Grade 2 |
10 (50%) |
| Grade 3 |
10 (50%) |
| T 1 |
0 (0%) |
| T 2 |
6 (30%) |
| T 3 |
12 (60%) |
| T 4 |
2 (10%) |
| N 0 |
8 (40%) |
| N 1 |
12 (60%) |
| N 2/3 |
0 (0%) |
| Triple negative |
6 (30%) |
| ER positive |
11 (55%) |
| PR positive |
10 (50%) |
| HER2 +ve |
6 (30%) |
| FEC |
6 (30%) |
| FEC-T |
13 (65%) |
| No chemotherapy | 1 (5%) |
Abbreviations: ER=estrogen receptor; FEC=5-fluorouracil, epirubicin and cyclophosphamide chemotherapy; FEC-T=5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel chemotherapy; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; PR=progesterone receptor.